Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews

References

• World Health Organization. Health topics/Coronavirus disease (COVID-19). Available at: https://www.who.int/health-topics/coronavirus#tab=tab_1 Cited 2022 Aug 10.
   Google Scholar
• World Health Organization. WHO coronavirus (COVID-19) dashboard. Cited 2022 Aug 10. Available at: https://covid19.who.int/.
   Google Scholar
• Centers for Disease Control and Prevention. Covid-19 vaccines for moderately to severely immunocompromised people. CDC. [Cited 2021 Sept 27]. www.cdc.gov/coronavirus/2019-ncov/vaccines/ recommendations/immuno.html
   Google Scholar
• Manuel O, Estabrook M. on behalf of the American Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13511.
   PubMed Web of Science ®Google Scholar
• Mohammed AH, Blebil A, Dujaili J, et al. The risk and impact of COVID-19 pandemic on immunosuppressed patients: cancer, HIV, and solid organ transplant recipients. AIDS Rev. 2020;22:151–157.
   PubMed Web of Science ®Google Scholar
• Madan A, Siglin J, Khan A. Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic. Cancer Med. 2020;9:9205–9218.
   PubMed Web of Science ®Google Scholar
• Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20:1800–1808.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Johnson SR, Anthony DD, et al. American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3. Arthritis Rheumatol. 2021;73:e60–75.
   PubMed Web of Science ®Google Scholar
• Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021;11:6283.
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Flight KE, Higham SL, et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021 Oct;21(10):626–636.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. C4591001 clinical trial group. safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• LR B, El SHM, Essink B, et al. COVE study group. efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022 Mar 2;376: e068632.
   PubMedGoogle Scholar
• Jrc S, PD K, Pham H, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 - COVID-NET, 10 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 8;71(27):878–884.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Robinson PC, Uldrick TS, et al. in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer. 2021 Jun;9(6):e002630.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19. N Engl J Med. 2022 Jun 9;386(23):2188–2200.
   PubMed Web of Science ®Google Scholar
• Riva JJ, Malik KM, Burnie SJ, et al. What is your research question? An introduction to the PICOT format for clinicians. J Can Chiropr Assoc. 2012;56(3):167–171.
   PubMedGoogle Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430–436.
   PubMed Web of Science ®Google Scholar
• Földi M, Farkas N, Kiss S, Zádori N, Váncsa S, Szakó L, Dembrovszky F, Solymár M, Bartalis E, Szakács Z, Hartmann P, Pár G, Erőss B, Molnár Z, Hegyi P, Szentesi A; KETLAK Study Group. Obesity is a risk factor for developing critical condition in COVID-19 patients: a systematic review and meta-analysis. Obes Rev. 2020 Oct;21(10):e13095.
   PubMed Web of Science ®Google Scholar
• Földi M, Farkas N, Kiss S, et al. Visceral adiposity elevates the risk of critical condition in COVID-19: a systematic review and meta-analysis. Obesity (Silver Spring). 2021 Mar;29(3):521–528.
   PubMed Web of Science ®Google Scholar
• Huang Y, Lu Y, Huang YM, Wang M, Ling W, Sui Y, Zhao HL. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020;113:154378. Dec.
   PubMed Web of Science ®Google Scholar
• Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020 Nov;21(11):e13128.
   PubMed Web of Science ®Google Scholar
• Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021 Jun;9(6):350–359.
   PubMed Web of Science ®Google Scholar
• Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021 Mar;17(3):135–149.
   PubMed Web of Science ®Google Scholar
• Sawadogo W, Tsegaye M, Gizaw A, et al. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: systematic review and meta-analysis. BMJ Nutr Prev Health. 2022 Jan 19;5(1):10–18.
   PubMedGoogle Scholar
• Sardu C, Marfella R, Prattichizzo F, et al. Effect of hyperglycemia on COVID-19 outcomes: vaccination efficacy, disease severity, and molecular mechanisms. J Clin Med. 2022 Mar 12;11(6):1564.
   PubMed Web of Science ®Google Scholar
• Ng SM, Pan J, Mouyis K, et al. Quantifying the Excess Risk of Adverse COVID-19 outcomes in unvaccinated individuals with diabetes mellitus, hypertension, ischaemic heart disease or myocardial injury: a meta-analysis. Front Cardiovasc Med. 2022 Apr 26;9: 871151.
   PubMed Web of Science ®Google Scholar
• Stefan N, Sippel K, Heni M, et al., Hrabe de Angelis M, Ludwig DS, Schulze MB, Jensen BEO, Birkenfeld AL. Obesity and Impaired metabolic health increase risk of COVID-19-related mortality in young and middle-aged adults to the level observed in older people: the LEOSS registry. Front Med. 2022 May 11; 9:875430. (Lausanne)
   Web of Science ®Google Scholar
• Marra AR, Kobayashi T, Suzuki H, et al. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis. J Infect. 2022 Mar;84(3):297–310.
   PubMed Web of Science ®Google Scholar
• Delavari S, Abolhassani H, Abolnezhadian F, et al. Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency. J Clin Immunol. 2021 Feb;41(2):345–355. Epub 2020 Dec 1
   PubMed Web of Science ®Google Scholar
• Shields AM, Tadros S, Al-Hakim A, et al. Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. Front Immunol. 2022 Sep 23;13: 984376.
   PubMed Web of Science ®Google Scholar
• SeyedAlinaghi S, Karimi A, Barzegary A, et al. mortality in patients with immunodeficiency and its predictors: a systematic review. Eur J Med Res. 2022 Oct 8;27(1):195.
   PubMed Web of Science ®Google Scholar
• Drzymalla E, Green RF, Knuth M, et al. COVID-19-related health outcomes in people with primary immunodeficiency: a systematic review. Clin Immunol. 2022Oct;243:109097.
   PubMed Web of Science ®Google Scholar
• Kang L, Shang W, Gao P, et al. and Safety of COVID-19 vaccines among people living with HIV: a systematic review and meta-analysis. Vaccines (Basel). 2022 Sep 19;10(9):1569.
   PubMed Web of Science ®Google Scholar
• Yin J, Chen Y, Li Y, et al. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis. Int J Infect Dis. 2022 Oct 12;124: 212–223.
   PubMed Web of Science ®Google Scholar
• Di Felice G, Visci G, Teglia F, et al. Effect of cancer on outcome of COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated patients. Elife. 2022 Feb 16;11: e74634.
   PubMed Web of Science ®Google Scholar
• Piechotta V, Mellinghoff SC, Hirsch C, et al. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. Blood Cancer J. 2022 May 31;12(5):86.
   PubMed Web of Science ®Google Scholar
• Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020 Oct 20;371: m3731.
   PubMedGoogle Scholar
• Monin L, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021 Jun;22(6):765–778.
   PubMed Web of Science ®Google Scholar
• Oosting SF, van der VAAM, GeurtsvanKessel CH, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021 Dec;22(12):1681–1691.
   PubMed Web of Science ®Google Scholar
• Cavanna L, Citterio C, Toscani I. COVID-19 vaccines in cancer patients. seropositivity and safety. systematic review and meta-analysis. Vaccines (Basel). 2021 Sep 20;9(9):1048.
   PubMed Web of Science ®Google Scholar
• Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, et al. Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022Jan;160:243–260.
   PubMed Web of Science ®Google Scholar
• Corti C, Antonarelli G, Scotté F, et al. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review. Ann Oncol. 2022 Feb;33(2):158–168.
   PubMed Web of Science ®Google Scholar
• Guven DC, Sahin TK, Kilickap S, et al. Antibody responses to COVID-19 vaccination in cancer: a systematic review. Front Oncol. 2021 Nov 4;11: 759108.
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Luna A, Micic D. Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. J Hematol Oncol. 2022 Feb 5;15(1):15.
   PubMed Web of Science ®Google Scholar
• Javadinia SA, Alizadeh K, Mojadadi MS, et al. Vaccination in patients with malignancy; A systematic review and meta-analysis of the efficacy and safety. Front Endocrinol (Lausanne). 2022 May 2;13: 860238.
   PubMed Web of Science ®Google Scholar
• Yang W, Zhang D, Li Z, et al. Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022Sep;172:41–50.
   PubMed Web of Science ®Google Scholar
• Tang K, Wei Z, Wu X. Impaired serological response to COVID-19 vaccination following anticancer therapy: a systematic review and meta-analysis. J Med Virol. 2022 Oct;94(10):4860–4868.
   PubMed Web of Science ®Google Scholar
• Martins-Branco D, Nader-Marta G, Tecic Vuger A, et al. Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2022Jul;22:1–6.
   Google Scholar
• Yin J, Chen Y, Li Y, et al. Seroconversion rate after COVID-19 vaccination in patients with solid cancer: a systematic review and meta-analysis. Hum Vaccin Immunother. 2022Sep;26:2119763.
   Google Scholar
• Al Hajji Y, Taylor H, Starkey T, et al. Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review. Br J Cancer. 2022Oct;12:1–10.
   Google Scholar
• Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021 Aug 9;39(8):1081–1090.e2.
   PubMed Web of Science ®Google Scholar
• Guven DC, Sahin TK, Akın S, et al. Impact of therapy in patients with hematologic malignancies on seroconversion rates after SARS-CoV-2 vaccination. Oncologist. 2022 Apr 5;27(4):e357–e361.
   PubMed Web of Science ®Google Scholar
• Kakkassery H, Carpenter E, Patten PEM, et al. Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. Trends Mol Med. 2022 Aug 3;S1471–4914(22):00186–1.
   Google Scholar
• Mehrabi Nejad MM, Moosaie F, Dehghanbanadaki H, et al. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis. Eur J Med Res. 2022;27(1):23.
   PubMed Web of Science ®Google Scholar
• Cho K, Park S, Kim EY, et al. Immunogenicity of COVID-19 vaccines in patients with diverse health conditions: a comprehensive systematic review. J Med Virol. 2022 Sep;94(9):4144–4155.
   PubMed Web of Science ®Google Scholar
• Gong IY, Vijenthira A, Betschel SD, et al. vaccine response in patients with hematologic malignancy: a systematic review and meta-analysis. Am J Hematol. 2022 Apr;97(4):E132–E135.
   PubMed Web of Science ®Google Scholar
• Teh JSK, Coussement J, Neoh ZCF, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv. 2022 Apr 12;6(7):2014–2034.
   PubMed Web of Science ®Google Scholar
• Rinaldi I, Pratama S, Wiyono L, et al. Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: systematic review and meta-analysis. Front Oncol. 2022 Aug 5;12: 951215.
   PubMedGoogle Scholar
• Noori M, Azizi S, Abbasi Varaki F, et al. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies. Int Immunopharmacol. 2022Sep;110:109046.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Passamonti F, Wolschke C, et al. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis. Haematologica. 2022 Aug 1;107(8):1840–1849.
   PubMed Web of Science ®Google Scholar
• Mai AS, Lee ARYB, Tay RYK, et al. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. Eur J Cancer. 2022Sep;172:65–75.
   PubMed Web of Science ®Google Scholar
• Fendler A, Shepherd STC, Au L, et al. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell. 2022;40(4):438.
   PubMed Web of Science ®Google Scholar
• Lee LYW, Starkey T, Ionescu MC, et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. Lancet Oncol. 2022 Jun;23(6):748–757.
   PubMed Web of Science ®Google Scholar
• Lee LYW, Ionescu MC, Starkey T, et al. UK Coronavirus Cancer Programme. COVID-19: third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: a population-based study. Eur J Cancer. 2022 Nov;175:1–10.
   PubMed Web of Science ®Google Scholar
• Kreuzberger N, Hirsch C, Andreas M, et al. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database Syst Rev. 2022 Aug 9;8(8):CD015021.
   PubMedGoogle Scholar
• An W, Wang Q, Kim TE, et al. Clinical characteristics and outcome of coronavirus disease 2019 infection in patients with solid organ transplants: a systematic review and meta-analysis. J Infect Public Health. 2022 Mar;15(3):365–372.
   PubMed Web of Science ®Google Scholar
• Gatti M, Rinaldi M, Bussini L, et al. ORCHESTRA study group. Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis. Clin Microbiol Infect. 2022 Aug;28(8):1057–1065.
   PubMed Web of Science ®Google Scholar
• Udomkarnjananun S, Kerr SJ, Townamchai N, et al. Mortality risk factors of COVID-19 infection in kidney transplantation recipients: a systematic review and meta-analysis of cohorts and clinical registries. Sci Rep. 2021 Oct 8;11(1):20073.
   PubMed Web of Science ®Google Scholar
• Akyol M, Çevik E, Ucku D, et al. Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: a systematic review. Tuberk Toraks. 2021 Dec;69(4):547–560.
   PubMed Web of Science ®Google Scholar
• Manothummetha K, Chuleerarux N, Sanguankeo A, et al. And risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in recipients of solid organ transplant: a systematic review and meta-analysis. JAMA Network Open. 2022 Apr 1;5(4):e226822.
   PubMed Web of Science ®Google Scholar
• Shoar S, ACC P-R, Patarroyo-Aponte G, et al. Immune response to SARS-CoV-2 vaccine among heart transplant recipients: a systematic review. Clin Med Insights Circ Respir Pulm Med. 2022 Jun 5;16: 11795484221105327.
   Web of Science ®Google Scholar
• Verleye A, Wijtvliet V, Abrams S, Hellemans R, Bougrea R, Massart A, Pipeleers L, Wissing KM, Ariën KK, De Winter BY, Van Damme P, Abramowicz D, Ledeganck KJ. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. Nephrol Dial Transplant. 2022 Jul 26;37(8):1566–1575.
   PubMedGoogle Scholar
• Zong K, Peng D, Yang H, et al. Risk factors for weak antibody response of SARS-CoV-2 vaccine in adult solid organ transplant recipients: a systemic review and meta-analysis. Front Immunol. 2022 Jun 14;13: 888385.
   PubMedGoogle Scholar
• Li J, Ayada I, Wang Y, et al. Factors associated with COVID-19 vaccine response in transplant recipients: a systematic review and meta-analysis. Transplantation. 2022 Oct 1;106(10):2068–2075.
   PubMed Web of Science ®Google Scholar
• Ge C, Du K, Luo M, et al. Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. Exp Hematol Oncol. 2022 Aug 16;11(1):46.
   PubMed Web of Science ®Google Scholar
• Meshram HS, Kute V, Rane H, et al. Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. 2022Aug;4:e13926.
   Google Scholar
• Sakuraba A, Luna A, Micic D. A systematic review and Meta-analysis of serologic response following coronavirus disease 2019 (COVID-19) vaccination in solid organ transplant recipients. Viruses. 2022 Aug 19;14(8):1822.
   PubMed Web of Science ®Google Scholar
• Ma BM, Tam AR, Chan KW, et al. Immunogenicity and safety of COVID-19 vaccines in patients receiving renal replacement therapy: a systematic review and meta-analysis. Front Med (Lausanne). 2022 Mar 9;9: 827859.
   PubMed Web of Science ®Google Scholar
• Luo D, Chen X, Du J, et al. Immunogenicity of COVID-19 vaccines in chronic liver disease patients and liver transplant recipients: a systematic review and meta-analysis. Liver Int. 2023 Jan;43(1):34–48.
   PubMed Web of Science ®Google Scholar
• El Karoui K, Hourmant M, Ayav C, et al. Vaccination and COVID-19 dynamics in dialysis patients. Clin J Am Soc Nephrol. 2022 Mar;17(3):395–402.
   PubMed Web of Science ®Google Scholar
• Cancarevic I, Nassar M, Daoud A, et al. Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis: a systematic review and meta-analysis. World J Virol. 2022 Sep 25;11(5):352–361.
   PubMedGoogle Scholar
• Sanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC Immune-response Study: the Immunogenicity, Tolerability, and Safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022 Apr 1;106(4):821–834.
   PubMed Web of Science ®Google Scholar
• Hilbrands LB, Duivenvoorden R, Vart P, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020 Nov 1;35(11):1973–1983.
   PubMed Web of Science ®Google Scholar
• Jager KJ, Kramer A, Chesnaye NC, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020 Dec;98(6):1540–1548.
   PubMed Web of Science ®Google Scholar
• De Meester J, De Bacquer D, Naesens M, et al. NBVN kidney registry group. incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study. J Am Soc Nephrol. 2021 Feb;32(2):385–396.
   PubMed Web of Science ®Google Scholar
• Yang L, Li J, Wei W, et al. Kidney health in the COVID-19 pandemic: an umbrella review of meta-analyses and systematic reviews. Front Public Health. 2022 Sep 12;10: 963667.
   PubMed Web of Science ®Google Scholar
• Iryaningrum MR, Supriyadi R, Lawrensia S, et al. Diabetes and mortality among patients with chronic kidney disease and COVID-19: a systematic review, meta-analysis, and meta-regression. Indian J Nephrol. 2022 July-August;32(4):327–333.
   PubMed Web of Science ®Google Scholar
• Tantisattamo E, Imhof C, Jager KJ, et al. ERACODA collaborators. Association of obesity with 3-month mortality in kidney failure patients with COVID-19. Clin Kidney J. 2022 Mar 21;15(7):1348–1360.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Lee TH, Tian YC, et al. Immunogenicity rates after SARS-CoV-2 vaccination in people with end-stage kidney disease: a systematic review and meta-analysis. JAMA Network Open. 2021 Oct 1;4(10):e2131749.
   PubMed Web of Science ®Google Scholar
• Mehta N, Shah S, Paudel K, et al. Safety and efficacy of coronavirus disease-19 vaccines in chronic kidney disease patients under maintenance hemodialysis: a systematic review. Health Sci Rep. 2022 Jun 16;5(4):e700.
   PubMedGoogle Scholar
• Peiyao R, Mengjie Y, Xiaogang S, et al. Immunogenicity and safety of SARS-CoV-2 vaccine in hemodialysis patients: a systematic review and meta-analysis. Front Public Health. 2022 Sep 23;10: 951096.
   PubMed Web of Science ®Google Scholar
• Falahi S, Sayyadi H, Kenarkoohi A. Immunogenicity of COVID-19 mRNA vaccines in hemodialysis patients: systematic review and meta-analysis. Health Sci Rep. 2022 Oct 3;5(6):e874.
   PubMedGoogle Scholar
• El Karoui K, De Vriese ASCOVID-19. in dialysis: clinical impact, immune response, prevention, and treatment. Kidney Int. 2022 May;101(5):883–894.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021 Aug 12;385(7):585–594.
   PubMed Web of Science ®Google Scholar
• Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021 May 1;397(10285):1646–1657.
   PubMed Web of Science ®Google Scholar
• Ismail SJ, Tunis MC, Zhao L, et al. Navigating inequities: a roadmap out of the pandemic. BMJ Glob Health. 2021;6(1):e004087.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med. 2022 Apr;28(4):831–837.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022 Apr 21;386(16):1532–1546.
   PubMed Web of Science ®Google Scholar
• Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022 Jan 27;386(4):340–350.
   PubMed Web of Science ®Google Scholar
• Vo AD, La J, Wu JT-Y, et al. Factors associated with severe COVID-19 among vaccinated adults treated in US veterans affairs hospitals. JAMA Network Open. 2022 Oct 3;5(10):e2240037.
   PubMed Web of Science ®Google Scholar
• Butsch WS, Hajduk A, Cardel MI, et al. COVID-19 vaccines are effective in people with obesity: a position statement from The Obesity Society. Obesity (Silver Spring). 2021 Oct;29(10):1575–1579.
   PubMed Web of Science ®Google Scholar
• Piernas C, Patone M, Astbury NM, et al. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2022 Aug;10(8):571–580.
   PubMedGoogle Scholar
• Kocivnik N, Velnar T. (2022). A review pertaining to SARS-CoV-2 and autoimmune diseases: what is the connection? Life (Basel, Switzerland). 12(11): 1918.
   PubMed Web of Science ®Google Scholar
• Garcillán B, Salavert M, Regueiro JR, et al. Response to vaccines in patients with immune-mediated inflammatory diseases: a narrative review. Vaccines (Basel). 2022;10(2):297.
   PubMed Web of Science ®Google Scholar
• Tang K-T, Hsu B-C, Chen D-Y. Immunogenicity, effectiveness, and safety of COVID-19 vaccines in rheumatic patients: an updated systematic review and meta-analysis. Biomedicines. 2022;10(4):834.
   PubMed Web of Science ®Google Scholar
• Sood A, Tran M, Murthy V, et al. Immunogenicity and safety of SARS-CoV-2 vaccination in patients with rheumatic diseases: a systematic review and meta-analysis. J Clin Rheumatol. 2022;28(8):381–389.
   PubMed Web of Science ®Google Scholar
• Sung K-Y, Chang T-E, Wang Y-P, et al. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: a systemic review and meta-analysis. J Chin Med Assoc. 2022;85(4):421–430.
   PubMed Web of Science ®Google Scholar
• Jena A, James D, Singh AK, et al. Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(7):1456–1479.e18.
   PubMed Web of Science ®Google Scholar
• Lee ARYB, Wong SY, Tay SH. Booster COVID-19 vaccines for immune-mediated inflammatory disease patients: a systematic review and meta-analysis of efficacy and safety. Vaccines (Basel). 2022 Apr 22;10(5):668.
   PubMed Web of Science ®Google Scholar
• Duly K, Farraye FA, Bhat S. COVID-19 vaccine use in immunocompromised patients: a commentary on evidence and recommendations. Am J Health Syst Pharm. 2022 Jan 5;79(2):63–71.
   PubMed Web of Science ®Google Scholar
• Mathieu E, Ritchie H, Rodés-Guirao L, et al. OurWorldInData: coronavirus Pandemic (COVID-19)- 2020. [Cited 2022 Oct 26]. Available at: https://ourworldindata.org/coronavirus
   Google Scholar
• European Medicines Agency. Evusheld: EPAR- assessment report, 2022. [Cited 2022 Oct 26]. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/evusheld
   Google Scholar
• Lafont E, Pere H, Lebeaux D, et al. SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19. J Antimicrob Chemother. 2022 Sep 30;77(10):2688–2692.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yuan H, Yang Z, et al. SARS-CoV-2: an updated review highlighting its evolution and treatments. Vaccines (Basel). 2022;10:2145.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Jiao B, Qu L, et al. The development of COVID-19 treatment. Front Immunol. 2023;14:1125246.
   PubMedGoogle Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. GS-US-540–9012 (PINETREE) Investigators. early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2022 Jan 27;386(4):305–315. Epub 2021 Dec 22
   PubMed Web of Science ®Google Scholar
• Widyasari K, Kim J. A review of the currently available antibody therapy for the treatment of coronavirus disease 2019 (COVID-19). Antibodies (Basel). 2023;12(1):5.
   PubMedGoogle Scholar
• RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022 Feb 12;399(10325):665–676.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941–1950. Epub 2021 Oct 27
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory Agency. Ronapreve 120 mg/ mL solution for injection or infusion. Summary of product characteristics. 2021 (https://assets.publishing.service.gov.uk/ government/uploads/system/uploads/ attachment_data/file/1012415/revisedgb spcronapreveclean120mg ml12aug2021docx.pdf). government/uploads/system/uploads/ attachment_data/file/1012415/revisedgb spcronapreveclean120mg ml12aug2021docx.pdf).
   Google Scholar
• Food and Drug Administration. Fact sheet for health care providers: emergency use authorization (EUA) of REGEN-COV (casirivimab and imdevimab). 2021 https://www.fda.gov/media/145611/download).a
   Google Scholar
• Food and Drug Administration. Fact sheet for health care providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. Jan 2022. (https://www.fda.gov/media/145802/download).b
   Google Scholar
• Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of sotrovimab. Feb 2022 (https://www.fda.gov/ media/149534/download).c
   Google Scholar
• Food and Drug Administration. Coronavirus (COVID-19) Drugs. Cited Jan 2023. Available at: https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs
   Google Scholar
• FDA updates Sotrovimab emergency use authorization. Cited January 2023. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization.
   Google Scholar
• Cavazzoni P. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron.
   Google Scholar
• Fact sheet for healthcare providers: emergency Use Authorization for Evusheld™ (tixagevimab co-packaged with cilgavimab). Cited Jan 2023. Available at: https://www.fda.gov/media/154701/download.
   Google Scholar
• European Medicines Agency. COVID-19 treatments: under evaluation. Cited Jan 2023. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-under-evaluation#covid-19-treatments-under-marketing-authorisation-evaluation-section.
   Google Scholar
• Evusheld Summary of Product Characteristics. Cited January 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/evusheld-epar-product-information_en.pdf.
   Google Scholar
• Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021 Jun 23;12: 698169.
   PubMed Web of Science ®Google Scholar
• Yomogida K, Zhu S, Rubino F, et al. Sequelae of SARS-CoV-2 infection among adults aged ≥18 years - Long Beach, California, April 1-December 10, 2020. MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1274–1277.
   PubMed Web of Science ®Google Scholar
• Brannock MD, Chew RF, Preiss AJ, et al. N3C and RECOVER consortia. long COVID risk and Pre-COVID vaccination: an EHR-based cohort study from the recover program. medRxiv [Preprint]. 2022 7;2022(Oct). DOI:10.1101/2022.10.06.22280795.
   Google Scholar
• Gao P, Liu J, Liu M. Effect of COVID-19 Vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022 Sep 29;19(19):12422.
   PubMed Web of Science ®Google Scholar